120 German Hospitals entitled to negotiate fee for OncoSil
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This marks a significant increase in hospital participation compared to the previous year, reflecting growing demand and recognition of the device in Germany. The approval follows earlier classifications and directives from German health authorities regarding the treatment method for pancreatic cancer. CEO Nigel Lange expressed optimism about the progress and acceptance of the OncoSil device among healthcare professionals in Germany.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from OncoSil Medical
- OncoSil Medical Receives MDR Approval
- OncoSil receives $1.05m R&D tax incentive
- Oncosil completes $1 million Share Purchase Plan (SPP)
- Prospectus 2024 Share Purchase Plan (SPP) Offer
- OSL completes $7 M Placement and announces $1 M SPP
Later from OncoSil Medical
- Consolidation/Split - OSL
- OSL announces $8.7m capital raise to drive commercialisation
- Completion of Recruitment in PANCOSIL Study
- Completion of Recruitment in TRIPP-FFX Clinical Trial
- Appendix 4E and Annual Report
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical